Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia
Status:
Not yet recruiting
Trial end date:
2023-08-21
Target enrollment:
Participant gender:
Summary
This is a single center Phase I clinical trial of FT538 administered intravenously (IV) once
every 14 days for 4 consecutive doses for the reduction of the HIV reservoir in lymphoid
tissue of HIV-infected individuals receiving standard of care (SOC) antiretroviral therapy
(ART). As this is an early 1st in human study and the 1st for HIV-infected individual, the
safety of FT538 is confirmed prior to the addition of oral vorinostat to explore the concept
of "Kick and Kill".